Rimouski (Quebec), February 7, 2018 – innoVactiv, a Canadian company dedicated to the development of science-based specialty ingredients, announces today that its latest human clinical study supporting the efficacy of InSea2® to beneficially affect post-meal cognition and mental energy has been accepted for publication in the January issue of the peer-reviewed journal Nutrients.
Under normal circumstances, post-meal fluctuations in blood glucose and insulin induce what is commonly felt as food coma. Based on its beneficial impact on post-meal blood glucose, it was hypothesized that InSea2® could help sustain brain function in this critical post-meal period. Recently, a human clinical trial conducted by the Brain, Performance and Nutrition Research Center of Northumbria University (UK) showed that InSea2® can help alleviate symptoms of food coma.
“We are really excited about these new results being published, as they open a new market segment for InSea2® as a caffeine-free support for cognition. Many persons feel the sudden urge to nap after eating or have other kinds of cognitive effects such as a decline in concentration. Using InSea2® before meal can support optimal cognition by promoting a healthier, more gradual absorption of dietary carbs and for avoiding large insulin release”, explains Jocelyn Bérubé, Executive Vice-President, Scientific and Regulatory Affairs at innoVactiv.